Facial Photodamage
Niadyne Pharma research has recently shown that impairment of skin barrier integrity is a common link between the cause of certain chronic skin diseases and the failure of drugs to effectively treat such conditions. That is, a degraded skin barrier not only is a major factor in the cause of these skin diseases, but current drug treatment often aggravates these conditions by further degrading the skin barrier. A degraded skin barrier causes the skin to become irritated to the point where drug therapy is often discontinued. Moreover, drug induced skin barrier impairment often leads to a worsening of the condition sometimes causing patients to discontinue therapy or accept suboptimal results. One of Niadyne's patented molecules has been clinically proven to improve the structure and function of the skin barrier. Newly approved drugs that are the result of combining these molecules with existing drugs will not only be able to provide superior treatment in the short term, but also create changes in the skin that will likely reduce the severity or probability of the disease reoccurring Ð a common complaint with much current therapy.
Skin barrier impairment caused by sun exposure is a major consequence of skin photodamage. The use of retinoids such as retinoic acid, the only drugs approved by the FDA to treat photodamaged skin, further degrade the skin barrier before therapeutic benefit takes place. As a result, patients often discontinue the use of this therapy due to the irritation caused by and associated with degrading the skin barrier. Niadyne Pharma has strong clinical data described in its dossier to support the claim that a combination NIA-114/retinoic acid drug will provide superior tolerability and improved efficacy. Such a drug will also allow for extended usage of retinoic acid thereby permitting the additional therapeutic benefit associated with its use on a long-term basis. The U.S. market for facial photodamage retinoid drugs is $150 million per year.
